Cytokine-based high log-scale expansion of functional human dendritic cells from cord-blood CD34-positive cells

Scientific Reports

Volumn 1, Issue , 2011, Pages

  Harada, Yui ^a,b   Okada Nakanishi, Yae ^b   Ueda, Yasuji ^a,d   Tsujitani, Shunichi ^c   Saito, Satoru ^a,b   Fuji Ogawa, Terumi ^a   Iida, Akihiro ^d   Hasegawa, Mamoru ^d   Ichikawa, Tomohiko ^a   Yonemitsu, Yoshikazu ^a,b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d DNAVEC Corporation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; CD34 ANTIGEN; CYTOKINE; GLYCOPROTEIN P 15095;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; CULTURE TECHNIQUE; CYTOLOGY; DENDRITIC CELL; FETUS BLOOD; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; IMMUNOTHERAPY; METABOLISM; T LYMPHOCYTE;

ANTIGENS, CD11C; ANTIGENS, CD34; CADHERINS; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; FETAL BLOOD; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOTHERAPY; T-LYMPHOCYTES;

EID: 84859746200     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00174     Document Type: Article

References (43)

1. Mathers, C. D. & Loncar, D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Med. 11, e442 (2006).
2. Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915 (2004). (Pubitemid 39273730)
3. Figdor, C. G., de Vries, I. J., Lesterhuis, W. J. & Melief, C. J. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10, 475-480 (2004). (Pubitemid 38667904)
4. Harada, Y. & Yonemitsu, Y. Recent developments in patented DC-based immunotherapy for various malignancies. Recent Patents on Regenerative Medicine 1, 72-87 (2011).
5. Tatsuta, K., et al. Complete elimination of established neuroblastoma by synergistic action of gamma-irradiation and DCs treated with rSeV expressing interferon-beta gene. Gene Ther. 16, 240-251 (2009).
6. Kato, T., et al. RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6. 3 prostate cancer. Neoplasia. 12, 906-914 (2010).
7. Small, E. J., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin Oncol 18, 3894-3903 (2000).
8. Harada, Y., et al. Cytokine-based log-scale expansion of functional murine dendritic cells. PLos ONE. 18, 4(8), e6674 (2009).
9. Bontkes, H. J., De Gruijl, T. D., Schuurhuis, G. J., Scheper, R. J., Meijer, C. J. & Hooijberg, E. Expansion of dendritic cell precursors from human CD341 progenitor cells isolated from healthy donor blood; growth factor combination determines proliferation rate and functional outcome. J. Leukoc Biol. 72, 321-329 (2002).
10. Fay, J. W., et al. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD341 progenitor-derived dendritic cells. Cancer Immunol. Immunother. 55, 1209-1218 (2006). (Pubitemid 43992047)
11. Banchereau, J., et al. Immune and clinical responses in patients with metastatic melanoma to CD34 progenitor-derived dendritic cell vaccine. Cancer Res. 61, 6451-6458 (2001). (Pubitemid 32783251)
12. Di Nicola, M., et al. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34-derived dendritic cell vaccination: A phase I trial in metastatic melanoma. Clin Cancer Res 10, 5381-5390 (2004). (Pubitemid 39100475)
13. Di Nicola, M., et al. Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34 cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial. Hum Gene Ther. 14, 1347-1360 (2003). (Pubitemid 37174758)
14. Mackensen, A., et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD341 hematopoietic progenitor cells. Int J. Cancer. 86, 385-92 (2000).
15. Warren, M. K., Rose, W. L., Cone, J. L., Rice, W. G. & Turpin, J. A. Differential infection of CD341cell-derived dendritic cells and monocytes with lymphocytetropic and monocyte-tropic HIV-1 strains. J. Immunol. 158, 5035-5042 (1997). (Pubitemid 127483830)
16. Caux, C., Saeland, S., Favre, C., Duvert, V., Mannoni, P. & Banchereau, J. Tumor necrosis factor-alpha strongly potentiates interleukin-3 and granulocytemacrophage colony-stimulating factor-induced proliferation of human CD341 hematopoietic progenitor cells. Blood. 75, 2292-2298 (1990). (Pubitemid 20202305)
17. Conti, L. & Gessani, S. GM-CSF in the generation of dendritic cells from human blood monocyte precursors: recent advances. Immunobiology. 213, 859-870 (2008).
18. Rondelli, D., et al. Rapid induction of CD40 on a subset of granulocyte colonystimulating factor-mobilized CD341 blood cells identifies myeloid committed progenitors and permits selection of nonimmunogenic CD401 progenitor cells. Blood 94, 2293-2300 (1999). (Pubitemid 29467677)
19. Lyman, S. D. & Jacobsen, S. E. C-Kit ligand and FLT3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood. 91, 1101-1134 (1998). (Pubitemid 28086863)
20. Szabolcs, P., Moore, M. A. & Young, J. W. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD341 bone marrow precursors cultured with c-Kit ligand, granulocyte-macrophage colonystimulating factor, and TNF-alpha. J. Immunol. 154, 5851-5861 (1995).
21. Ratta, M., et al. Generation and functional characterization of human dendritic cells derived from CD341cells mobilized into peripheral blood: comparison with bone marrow CD341 cells. Br. J. Haematol. 101, 756-765 (1998). (Pubitemid 28308528)
22. Balan, S., Kale, V. P. & Limaye, L. S. A simple two-step culture system for the large-scale generation of mature and functional dendritic cells from umbilical cord blood CD341 cells. Transfusion. 49, 2109-2121 (2009).
23. Kato, T., Ueda, Y., Kinoh, H., Tsukada, K., Ichikawa, T. & Yonemitsu, Y. Pathogen-related signal transduction pathways of dendritic cells: perspectives for cancer immunotherapy. Front. Biosci. 3, 133-137 (2008).
24. Okamoto, M., et al. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res. 64, 5461-5470 (2004). (Pubitemid 39006570)
25. Nakahara, S., Tsunoda, T., Baba, T., Asabe, S. & Tahara, H. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res. 63, 4112-4118 (2003). (Pubitemid 36917935)
26. Shibata, S., et al. Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene. J Immunol. 177, 3564-3576 (2006). (Pubitemid 44359887)
27. Nagayama, H., et al. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res. 13, 521-530 (2003). (Pubitemid 37266955)
28. Trefzer, U., et al. Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int J Cancer. 110, 730-740 (2004). (Pubitemid 38746032)
29. Obermajer, N., Svajger, U., Bogyo, M., Jeras, M. & Kos, J. Maturation of dendritic cells depends on proteolytic cleavage by cathepsin X. J Leukoc Biol. 84, 1306-1315 (2008).
30. Kuroki, H., et al. Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother. 52, 561-568 (2003). (Pubitemid 37056131)
31. Nakahara, S., Tsunoda, T., Baba, T., Asabe, S. & Tahara, H. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res. 63, 4112-4118 (2003). (Pubitemid 36917935)
32. Monks, C. R., Freiberg, B. A., Kupfer, H., Sciaky, N. & Kupfer, A. Threedimensional segregation of supramolecular activation clusters in T cells. Nature. 395, 82-86 (1998). (Pubitemid 28420234)
33. Dustin, M. L., et al. A novel adapter protein orchestrates receptor patterning and cytoskeletal polarity in T cell contacts. Cell 94, 667-677 (1998). (Pubitemid 28427585)
34. Dustin, M. L. & Shaw, A. S. Costimulation: building an immunological synapse. Science 283, 649-650 (1999).
35. Dustin, M. L., Tseng, S. Y., Varma, R. & Campi, G. T cell-dendritic cell immunological synapses. Curr Opin Immunol. 18, 512-516 (2006). (Pubitemid 43947585)
36. Soligo, D., Lambertenghi Deliliers, G., Quirici, N., Servida, F., Caneva, L. & Lamorte, G. Expansion of dendritic cell derived from human CD341 cells in static and continuous perfusion cultures. Br J. Haematol. 101, 352-363 (1998). (Pubitemid 28261127)
37. Curti, A., Fogli, M., Ratta, M., Tura, S. & Lemoli, R. M. Stem cell factor and FLT3-ligand are strictly required to sustain the long-term expansion of primitive CD341DR-dendritic cell precursors. J. Immunol. 166, 848-854 (2001). (Pubitemid 32060237)
38. Sioud, M. & Fløisand, Y. TLR agonists induce the differentiation of human bone marrow CD341 progenitors into CD11c1 CD80/861 DC capable of inducing a Th1-type response. Eur J. Immunol. 37, 2834-2846 (2007). (Pubitemid 47578303)
39. Komaru, A., et al. Sustained and NK/CD41T cell-dependent efficient prevention of lung metastasis induced by dendritic cells harboring recombinant Sendai virus. J. Immunol 183, 4211-4219 (2009).
40. Yasuda, T., et al. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol Immunother, 56, 1025-1036 (2007). (Pubitemid 46675296)
41. Merrick, A., Diaz, R. M., O'Donnell, D., Selby, P., Vile, R. & Melcher, A. Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naive cytotoxic priming and anti-tumour therapy. Cancer Immunol Immunother, 57, 897-906 (2008).
42. Li, H. O., et al. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J. Virol. 74, 6564-6569 (2000).
43. Yonemitsu, Y., et al. Efficient gene transfer to the airway epithelium using recombinant Sendai virus. Nat Biotechnol. 18, 970-973 (2000). (Pubitemid 32977378)